BRD4 interacts with PML/RARα in acute promyelocytic leukemia / 医学前沿
Frontiers of Medicine
;
(4): 726-734, 2018.
Article
in English
| WPRIM
| ID: wpr-771271
ABSTRACT
Bromodomain-containing 4 (BRD4) has been considered as an important requirement for disease maintenance and an attractive therapeutic target for cancer therapy. This protein can be targeted by JQ1, a selective small-molecule inhibitor. However, few studies have investigated whether BRD4 influenced acute promyelocytic leukemia (APL), and whether BRD4 had interaction with promyelocytic leukemia-retinoic acid receptor α (PML/RARα) fusion protein to some extent. Results from cell viability assay, cell cycle analysis, and Annexin-V/PI analysis indicated that JQ1 inhibited the growth of NB4 cells, an APL-derived cell line, and induced NB4 cell cycle arrest at G1 and apoptosis. Then, we used co-immunoprecipitation (co-IP) assay and immunoblot to demonstrate the endogenous interaction of BRD4 and PML/RARα in NB4 cells. Moreover, downregulation of PML/RARα at the mRNA and protein levels was observed upon JQ1 treatment. Furthermore, results from the RT-qPCR, ChIP-qPCR, and re-ChIP-qPCR assays showed that BRD4 and PML/RARα co-existed on the same regulatory regions of their target genes. Hence, we showed a new discovery of the interaction of BRD4 and PML/RARα, as well as the decline of PML/RARα expression, under JQ1 treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Azepines
/
Transcription Factors
/
Triazoles
/
RNA, Messenger
/
Nuclear Proteins
/
Tumor Cells, Cultured
/
Leukemia, Promyelocytic, Acute
/
Down-Regulation
/
Gene Expression Regulation, Neoplastic
Limits:
Humans
Language:
English
Journal:
Frontiers of Medicine
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS